TWI675026B - 稠環衍生物、其製備方法、中間體、藥物組合物及應用 - Google Patents

稠環衍生物、其製備方法、中間體、藥物組合物及應用 Download PDF

Info

Publication number
TWI675026B
TWI675026B TW105109178A TW105109178A TWI675026B TW I675026 B TWI675026 B TW I675026B TW 105109178 A TW105109178 A TW 105109178A TW 105109178 A TW105109178 A TW 105109178A TW I675026 B TWI675026 B TW I675026B
Authority
TW
Taiwan
Prior art keywords
compound
mmol
group
added
solution
Prior art date
Application number
TW105109178A
Other languages
English (en)
Chinese (zh)
Other versions
TW201641491A (zh
Inventor
祖盛 許
張農
孫慶瑞
吳添智
Original Assignee
上海瓔黎藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海瓔黎藥業有限公司 filed Critical 上海瓔黎藥業有限公司
Publication of TW201641491A publication Critical patent/TW201641491A/zh
Application granted granted Critical
Publication of TWI675026B publication Critical patent/TWI675026B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW105109178A 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用 TWI675026B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
??201510131828.5 2015-03-24
CN201510131828 2015-03-24
CN201610071297.XA CN106008340B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
??201610071297.X 2016-02-01

Publications (2)

Publication Number Publication Date
TW201641491A TW201641491A (zh) 2016-12-01
TWI675026B true TWI675026B (zh) 2019-10-21

Family

ID=56977003

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105109178A TWI675026B (zh) 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用
TW106139600A TWI666201B (zh) 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106139600A TWI666201B (zh) 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用

Country Status (14)

Country Link
US (2) US10100015B2 (https=)
EP (1) EP3275867B1 (https=)
JP (1) JP6449482B2 (https=)
KR (1) KR102087918B1 (https=)
CN (3) CN106008340B (https=)
AU (1) AU2016236669B2 (https=)
CA (1) CA2980484C (https=)
IL (1) IL254098B (https=)
MX (1) MX383376B (https=)
NZ (1) NZ735044A (https=)
RU (1) RU2683566C1 (https=)
SG (1) SG11201706869XA (https=)
TW (2) TWI675026B (https=)
WO (1) WO2016150255A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2017012559A1 (zh) * 2015-07-21 2017-01-26 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
US10829483B2 (en) * 2016-05-23 2020-11-10 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108033909A (zh) * 2017-12-20 2018-05-15 北京六合宁远科技有限公司 一种6-甲基-4-溴-异喹啉的制备方法
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111303161B (zh) * 2020-04-14 2021-01-05 遵义医科大学珠海校区 嘧啶并氮杂环类化合物及其用途
CN111763218B (zh) * 2020-07-14 2021-05-28 山东大学 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用
US20250059202A1 (en) 2022-01-04 2025-02-20 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of fused ring derivative, and preparation method therefor and use thereof
CN116465985B (zh) * 2023-03-03 2024-12-10 连云港杰瑞药业有限公司 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
CN118955327A (zh) * 2024-06-26 2024-11-15 安徽大学 一种4-溴-1-萘甲腈的合成方法
CN118878551B (zh) * 2024-07-08 2026-04-28 安徽大学 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021598A1 (en) * 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
CN102482220A (zh) * 2009-08-06 2012-05-30 安斯泰来制药有限公司 含氮环酰基胍衍生物
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
WO2014177596A1 (en) * 2013-05-03 2014-11-06 F. Hoffmann-La Roche Ag Neurogenesis-stimulating isoquinoline derivatives
WO2015027222A2 (en) * 2013-08-23 2015-02-26 Neupharma, Inc. Certain chemical entities, compositions, and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558655A (en) * 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US4224330A (en) 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
AUPO282896A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005063828A1 (en) * 2003-12-22 2005-07-14 Basell Polyolefine Gmbh Metallocene compounds
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
US20090012097A1 (en) * 2006-01-30 2009-01-08 Irm Llc Polycyclic 1,2,3,4-Tetrahydro-Isoquinoline Derivatives and Compositions Comprising Them As Ppar Modulators
JPWO2007105753A1 (ja) 2006-03-16 2009-07-30 アステラス製薬株式会社 トリアゾール誘導体またはその塩
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
JP2011520809A (ja) * 2008-05-05 2011-07-21 アムジエン・インコーポレーテツド γセクレターゼモジュレーターとしての尿素化合物
US8809382B2 (en) * 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
US8969349B2 (en) * 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
BR112012032193A2 (pt) * 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
PE20141002A1 (es) 2010-10-27 2014-08-17 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas
US8957203B2 (en) * 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
CN104812387A (zh) * 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶
BR112017013465A2 (pt) * 2014-12-24 2018-03-06 Lg Chem, Ltd derivado de biarila, e, composição farmacêutica.
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021598A1 (en) * 1999-09-23 2001-03-29 Astrazeneca Ab Therapeutic quinazoline compounds
CN102482220A (zh) * 2009-08-06 2012-05-30 安斯泰来制药有限公司 含氮环酰基胍衍生物
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
WO2014177596A1 (en) * 2013-05-03 2014-11-06 F. Hoffmann-La Roche Ag Neurogenesis-stimulating isoquinoline derivatives
WO2015027222A2 (en) * 2013-08-23 2015-02-26 Neupharma, Inc. Certain chemical entities, compositions, and methods

Also Published As

Publication number Publication date
MX383376B (es) 2025-03-13
IL254098B (en) 2020-03-31
CN106008340B (zh) 2020-03-17
CN108299425B (zh) 2020-09-18
EP3275867A4 (en) 2018-01-31
CA2980484A1 (en) 2016-09-29
JP6449482B2 (ja) 2019-01-09
AU2016236669A1 (en) 2017-09-21
CN108516958B (zh) 2020-07-17
TW201641491A (zh) 2016-12-01
TW201808909A (zh) 2018-03-16
HK1226055A1 (zh) 2017-09-22
CN106008340A (zh) 2016-10-12
KR20170123705A (ko) 2017-11-08
EP3275867B1 (en) 2020-06-10
TWI666201B (zh) 2019-07-21
NZ735044A (en) 2018-10-26
CN108299425A (zh) 2018-07-20
AU2016236669B2 (en) 2018-11-08
EP3275867A1 (en) 2018-01-31
KR102087918B1 (ko) 2020-03-12
CN108516958A (zh) 2018-09-11
WO2016150255A1 (zh) 2016-09-29
RU2683566C1 (ru) 2019-03-29
JP2018509451A (ja) 2018-04-05
US10100016B2 (en) 2018-10-16
US20180072678A1 (en) 2018-03-15
SG11201706869XA (en) 2017-09-28
CA2980484C (en) 2019-11-26
US10100015B2 (en) 2018-10-16
MX2017012009A (es) 2018-06-06
IL254098A0 (en) 2017-10-31
US20180265476A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
TWI675026B (zh) 稠環衍生物、其製備方法、中間體、藥物組合物及應用
TWI833829B (zh) 聯苯類化合物，其中間體，製備方法，藥物組合物及應用
EP3927693B1 (en) 2-phenyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile derivatives and similar compounds as thyroid hormone receptor agonists for the treatment of e.g. obesity
TWI853806B (zh) 小分子pd-1/pd-l1抑制劑、其與pd-l1抗體的藥物組合物及其應用
IL286069B1 (en) Pyrazine derivative and application thereof in inhibiting shp2
CN109071498A (zh) 激酶抑制剂及其制备方法和用途
JP7530510B2 (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
TWI817191B (zh) 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
WO2010059549A1 (en) Prolyl hydroxylase inhibitors
KR20150079677A (ko) 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
JP2018087173A (ja) 悪性脳腫瘍治療薬
HK1226055B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
HK40052029A (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
HK40035588A (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
HK40035588B (en) Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
EA018001B1 (ru) 3-индазолил-4-пиридилизотиазолы
JPWO1999035142A1 (ja) ４−（３−インドリル）イミダゾール誘導体